These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 37701519)
21. A Plain Language Summary of "Dostarlimab for primary advanced or recurrent endometrial cancer". Mirza MR; Chase DM; Slomovitz BM; Christensen RD; Novák Z; Black D; Gilbert L; Sharma S; Valabrega G; Landrum LM; Hanker LC; Stuckey A; Boere I; Gold MA; Auranen A; Pothuri B; Cibula D; McCourt C; Raspagliesi F; Shahin MS; Gill SE; Monk BJ; Buscema J; Herzog TJ; Copeland LJ; Tian M; He Z; Stevens S; Zografos E; Coleman RL; Powell MA Future Oncol; 2024 Jul; ():1-18. PubMed ID: 38990090 [TBL] [Abstract][Full Text] [Related]
22. The Revolution of Immunotherapy in Gynecological Cancers: The Lazarus Effect in Endometrial Cancer. Ducceschi M; Polignano M; Bini M; Lopez S; Conca E; Tamborini E; Perrone F; Carlo Stella G; Petrella MC; Carciotto R; Artioli G; Maffeis V; Sartor L; Raspagliesi F; Mantiero M J Clin Med; 2023 Aug; 12(17):. PubMed ID: 37685607 [TBL] [Abstract][Full Text] [Related]
23. Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study. Nadler E; Arondekar B; Aguilar KM; Zhou J; Chang J; Zhang X; Pawar V J Cancer Res Clin Oncol; 2021 Mar; 147(3):671-690. PubMed ID: 33263865 [TBL] [Abstract][Full Text] [Related]
24. Comparative analysis of PD-1 target engagement of dostarlimab and pembrolizumab in advanced solid tumors using ex vivo IL-2 stimulation data. Austin D; Melhem M; Gandhi Y; Lu S; Visser S CPT Pharmacometrics Syst Pharmacol; 2023 Jan; 12(1):87-94. PubMed ID: 36317409 [TBL] [Abstract][Full Text] [Related]
25. Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial. Patnaik A; Weiss GJ; Rasco DW; Blaydorn L; Mirabella A; Beeram M; Guo W; Lu S; Danaee H; McEachern K; Im E; Sachdev JC Cancer Chemother Pharmacol; 2022 Jan; 89(1):93-103. PubMed ID: 34750637 [TBL] [Abstract][Full Text] [Related]
26. Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. Kasherman L; Ahrari S; Lheureux S Future Oncol; 2021 Mar; 17(8):877-892. PubMed ID: 33251877 [TBL] [Abstract][Full Text] [Related]
27. Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data. Pérol M; Felip E; Dafni U; Polito L; Pal N; Tsourti Z; Ton TGN; Merritt D; Morris S; Stahel R; Peters S Ann Oncol; 2022 May; 33(5):511-521. PubMed ID: 35218887 [TBL] [Abstract][Full Text] [Related]
28. An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer. Bartoletti M; Giorda G; Viel A; Fornasarig M; Zdjelar A; Segatto E; Sorio R; Corsetti S; Scalone S; Nicoloso MS; Pivetta T; Lucia E; Clemente N; Palazzari E; Canzonieri V; Puglisi F Curr Oncol; 2022 Jul; 29(8):5209-5212. PubMed ID: 35892982 [TBL] [Abstract][Full Text] [Related]
29. Dostarlimab: A promising new PD-1 inhibitor for cancer immunotherapy. Farzeen Z; Khan RRM; Chaudhry AR; Pervaiz M; Saeed Z; Rasheed S; Shehzad B; Adnan A; Summer M J Oncol Pharm Pract; 2024 Dec; 30(8):1411-1431. PubMed ID: 39056234 [TBL] [Abstract][Full Text] [Related]
30. FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision-making in real-world. Marschner N; Hegewisch-Becker S; Reiser M; von der Heyde E; Bertram M; Hollerbach SH; Kreher S; Wolf T; Binninger A; Chiabudini M; Kaiser-Osterhues A; Jänicke M; Int J Cancer; 2023 Feb; 152(3):458-469. PubMed ID: 36053905 [TBL] [Abstract][Full Text] [Related]
31. Population pharmacokinetics and exposure-response of anti-programmed cell death protein-1 monoclonal antibody dostarlimab in advanced solid tumours. Melhem M; Hanze E; Lu S; Alskär O; Visser S; Gandhi Y Br J Clin Pharmacol; 2022 Sep; 88(9):4142-4154. PubMed ID: 35357027 [TBL] [Abstract][Full Text] [Related]
32. Treatment Patterns and Outcomes Among Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States. Coleman RL; Garside J; Hurteau J; Nguyen J; Kobayashi M J Health Econ Outcomes Res; 2023; 10(2):82-90. PubMed ID: 37905183 [No Abstract] [Full Text] [Related]
33. Considerations for the Utility of Real-World Evidence Beyond Trial Data in Advanced NSCLC: The Case of Frontline Tyrosine Kinase Inhibitors. Gaitonde P; Chirikov V; Kelkar S; Liljas B Cancer Manag Res; 2022; 14():3421-3435. PubMed ID: 36514307 [TBL] [Abstract][Full Text] [Related]
34. An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations. Chouaid C; Bosquet L; Girard N; Kron A; Scheffler M; Griesinger F; Sebastian M; Trigo J; Viteri S; Knott C; Rodrigues B; Rahhali N; Cabrieto J; Diels J; Perualila NJ; Schioppa CA; Sermon J; Toueg R; Erdmann N; Mielke J; Nematian-Samani M; Martin-Fernandez C; Pfaira I; Li T; Mahadevia P; Wolf J Adv Ther; 2023 Mar; 40(3):1187-1203. PubMed ID: 36652175 [TBL] [Abstract][Full Text] [Related]
35. Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer that are non-microsatellite instability high (non-MSI-high) or mismatch repair proficient (pMMR) in the United States. Kelkar SS; Prabhu VS; Zhang J; Corman S; Macahilig C; Rusibamayila N; Odak S; Duska LR Gynecol Oncol Rep; 2022 Aug; 42():101026. PubMed ID: 35800987 [TBL] [Abstract][Full Text] [Related]
36. Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer who are microsatellite instability (MSI)-high or are mismatch repair deficient (dMMR) in the United States. Kelkar SS; Prabhu VS; Corman S; Odak S; Rusibamayila N; Macahilig C; Orlowski R; Duska L Gynecol Oncol; 2023 Feb; 169():154-163. PubMed ID: 36344294 [TBL] [Abstract][Full Text] [Related]
37. An Integrated Analysis of Dostarlimab Immunogenicity. Lu S; Bowsher RR; Clancy A; Rosen A; Zhang M; Yang Y; Koeck K; Gao M; Potocka E; Guo W; Jen KY; Im E; Milton A AAPS J; 2021 Jul; 23(5):96. PubMed ID: 34324079 [TBL] [Abstract][Full Text] [Related]
38. Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study. van Zeijl MCT; Haanen JBAG; Wouters MWJM; de Wreede LC; Jochems A; Aarts MJB; van den Berkmortel FWPJ; de Groot JWB; Hospers GAP; Kapiteijn EW; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; van der Hoeven KJM; van den Eertwegh AJM J Immunother; 2020 Oct; 43(8):256-264. PubMed ID: 32804914 [TBL] [Abstract][Full Text] [Related]
39. Real-World Treatment Patterns and Outcomes of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma Treated in US Oncology Practices. Ge W; Wu N; Chen CI; Inocencio TJ; LaFontaine PR; Seebach F; Fury M; Harnett J; Ruiz ES Cancer Manag Res; 2024; 16():841-854. PubMed ID: 39050978 [TBL] [Abstract][Full Text] [Related]